L-DOPA-13C6
Based on 1 Customer Validation
L-DOPA-13C6 is the 13C-labled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.11%
- CAS No.: 201417-12-1
- Formule: C313C6H11NO4
- Masse moléculaire:203.14
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Dopamine Receptor
MoreVoir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 201417-12-1
-
Unlabeled CAS 59-92-7
-
Appearance Solid
-
Masse moléculaire 203.14
-
Formule C313C6H11NO4
-
Color White to off-white
-
SMILES
OC([C@@H](N)C[13C]1=[13CH][13C](O)=[13C]([13CH]=[13CH]1)O)=O
-
Synonyms
Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
H2O : 10 mg/mL (49.23 mM; ultrasonic and adjust pH to 1 with 1 M HCl)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]
[3]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814(4):273-80. Epub 2007 Nov 7. [Content Brief]
[4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237. [Content Brief]
[5]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154(2):330-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.9227 mL | 24.6136 mL | 49.2271 mL | 123.0678 mL |
| 5 mM | 0.9845 mL | 4.9227 mL | 9.8454 mL | 24.6136 mL | |
| 10 mM | 0.4923 mL | 2.4614 mL | 4.9227 mL | 12.3068 mL | |
| 15 mM | 0.3282 mL | 1.6409 mL | 3.2818 mL | 8.2045 mL | |
| 20 mM | 0.2461 mL | 1.2307 mL | 2.4614 mL | 6.1534 mL | |
| 25 mM | 0.1969 mL | 0.9845 mL | 1.9691 mL | 4.9227 mL | |
| 30 mM | 0.1641 mL | 0.8205 mL | 1.6409 mL | 4.1023 mL | |
| 40 mM | 0.1231 mL | 0.6153 mL | 1.2307 mL | 3.0767 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
L-DOPA-13C6 Related Classifications
HY-N0304S1 Related Classifications
Powered by Bioz